Published in Volume 112, Issue 2
J. Clin. Invest. 112(2): 149-151 (2003). doi:10.1172/JCI19143.
Copyright © 2003, The American Society for Clinical Investigation

Commentary

Salicylic acid: an old dog, new tricks, and staphylococcal disease

Mathias Herrmann

Department of Bacteriology and Hygiene, Institute of Medical Microbiology and Hygiene, University of Saarland, Homburg/Saar, Germany

Address correspondence to: Mathias Herrmann, Department of Bacteriology and Hygiene, Institute of Microbiology and Hygiene, Building 43, Kirrberger Street, 66421 Homburg/Saar, Germany. Phone: 49-6841-162-3900; Fax: 49-6841-162-3985; E-mail: mathias.herrmann@uniklinik-saarland.de.

Aspirin has been shown to cause a reduction in the virulence of Staphylococcus aureus–associated endocarditis. A new study reveals that salicylic acid, the major metabolite of aspirin, acts at the level of transcription to downregulate the production of fibrinogen, fibronectin, and α-hemolysin — virulence factors necessary for bacterial replication in host tissues and, now, potential therapeutic targets.

See the related article beginning on page 222.

One hundred and twenty years after its initial description as the pathogen that causes sepsis and abscesses (1), Staphylococcus aureus remains a dangerous organism. Staphylococcal endocarditis is on the rise (2) and still causes significant mortality (3). The methicillin-resistant S. aureus (MRSA) epidemic has entered a new era due to the spread of MRSA into the community (4) and acquisition of new resistance cassettes with the potential for genetic transfer (5). The advent of fully vancomycin-resistant, methicillin-resistant clinical isolates (6) has further weakened the available armamentarium against this pathogen.

Importance of staphylococcal attachment and invasion in endovascular disease

S. aureus is a nonmotile microorganism with a particular propensity to colonize biologic or artificial substrates using a battery of pathogenicity factors (7), allowing for specific bacterial attachment. This can be followed by cellular invasion and subsequent tissue degradation. Several lines of evidence clearly indicate that the interaction with host proteins and platelets is instrumental in the development of disease. A plethora of bacterial factors — either wall bound (8) or secreted (9, 10) — mediate binding of and attachment to ECM molecules such as fibronectin, fibrinogen, collagen, and vWF. Work with deletion mutants and complemented heterologous hosts has demonstrated the particular role of adhesins that recognize fibronectin (such as fibronectin-binding protein A) and fibrinogen (such as clumping factor A, ClfA), allowing for cellular invasion and production of experimental endocarditis (11, 12), and gfp reporter assays from endocarditis models clearly indicate that activation of global regulators that coordinate adhesin and toxin expression, such as agr and sar, occurs in vivo (13, 14).

Distinctive effects of acetylsalicylic acid and salicylic acid on platelets and bacteria

A particular role of platelets in the pathogenesis of staphylococcal endocarditis has been suggested since the early observation by Durack of bacterial interaction with fibrin-platelet matrices at sites of nonbacterial thrombotic endocarditis (15) and the series of reports by Clawson et al. on the interaction of S. aureus with purified platelets (16). In the early 1990s, experiments with surface-activated platelets suggested to our group the importance of fibrinogen and S. aureus clumping factor in the bacteria-platelet interaction (17). These observations were subsequently confirmed and extended by use of a low-platelet-binding mutant expressing a mutated ClfA protein (18) that displays diminished virulence in an endocarditis model (19), and by identification of the secreted fibrinogen-binding proteins Coa and Efb in phage-display panning assays (20) (Figure 1).

Figure 1

Pathogenic events resulting in endovascular disease. Local inflammation activates the binding of fibronectin by ECs through vascular cell adhesion molecules; platelet activation is triggered by cytokines and tissue factor (TF) secreted by monocytes and ECs. Fibronectin also mediates invasion of ECs by S. aureus, allowing for persistence and intracellular growth shielded from host defense. The inflammatory response mediated by T cells and polymorphonuclear neutrophils (PMNs) may be mitigated by the effect of Eap (39, 40). MO, monocyte.

While these observations pointed toward complex but, according to their adhesive function, rather propathogenic events at the bacteria-endocardium interface, the role of platelets had to be reevaluated after the discovery that they function as specialized inflammatory cells (21) in response to secretion of antimicrobial peptides. In fact, paradoxically, hyperexpression of α-toxin by S. aureus results in diminished virulence in experimental endocarditis, possibly because of the release of platelet microbicidal proteins (22).

The attributed role of platelets in the disease process that results in endovascular infection has prompted a number of researchers to interfere with platelet function for prevention or treatment of endocarditis. Acetylsalicylic acid (ASA, aspirin) has been used in vitro and in a number of experimental models to reduce vegetation sizes and to mitigate the course of disease (23–25). Similar effects have also been observed by Kupferwasser et al. (26). However, when they studied its metabolite, salicylic acid (SAL), in parallel to ASA, they made the interesting observation that pretreatment of bacteria with SAL reduced attachment to the valvular epithelium to an even greater extent than administration of ASA. This observation was accompanied by the in vitro finding that SAL-pretreated S. aureus cells bound to a lesser degree to platelets and to fibrin-platelet and fibrin matrices than did untreated bacteria and elicited platelet aggregation in a prolonged reaction time. Since SAL lacks the key effect of ASA on platelet function consisting of acetylation of the platelet COX-1, the observed in vivo attenuation and in vitro adherence studies delineated distinct effects of ASA and SAL on platelets and microorganisms, respectively.

SAL modulates key regulatory steps in pathogenesis

In this issue of the JCI, Kupferwasser and colleagues (27) extend these exciting findings. In a careful approach using a number of strains with functional gene regulator deletions and complementations in various genetic backgrounds, they demonstrated an acid stress–independent, SAL-mediated activation of the alternative staphylococcal stress response gene sigB, and consequently a downregulation of the sarA and agr regulons with a concomitant decrease in the expression of hla and fnbA (Figure 2). These effects resulted in decreased bacterial adherence, and reduced toxin-mediated hemolysis and thrombolysis. Most importantly, SAL pretreatment attenuated the course of disease by decreasing the vegetation weight, the vegetation bacterial density, and the renal bacterial density.

Figure 2

Potential roles of salicylic acid (SAL) in the pathogenesis of S. aureus endovascular infection. (I) SAL pretreatment of S. aureus results in overexpression of SigB-dependent genes in both an rsbU-positive and an rsbU-negative background, suggesting SigB activation independent of the anti–ς-factor RsbU. (II) Activation of the sarAP3 promotor appears to contribute to decreased expression of active SarA protein, putatively via inhibitory activity of the sarAP3 gene product. Again, SAL appears to contribute to SarA reduction in a sarAP3-additive fashion. (III) As SarA controls expression of RNAII and RNAIII, the net effect of SAL is a mitigation of the agr response. Since α-toxin (hla) expression depends on both sar and agr, and expression of wall-bound adhesins is also in part controlled by sar, the mitigation of both adhesin and toxin expression in SAL-treated microorganisms appears to depend on a combined sar/agr effect; yet other regulators may also be involved. (IV) In addition to hla, the expression of other secreted molecules such as the extracellular adhesive protein Eap depends on agr and sarA and may be downregulated under the influence of SAL. Expression of the polysaccharide intracellular adhesin (PIA) is suggested to depend on sigB, which may positively control expression of icaADBC, with consequences not yet fully understood in S. aureus endovascular infection. The S. aureus adhesins (FnBPA, FnBPB, ClfA, and ClfB) recognize fibronectin and fibrinogen, which are presented on ECs and platelets.

The role of sarA and agr in the course of experimental endocarditis has already been studied previously by this group (28). What is novel in this approach is delineation of the effect of SAL on the global regulators, which induces a downregulated status of functional sarA and agr. The nature of agr as a two-component signal transduction–dependent regulator may allow for autoinduction and bacterial interference (29). Another approach to the attenuation of virulence is inhibition of the electron transport (30) that drives microorganisms in a small-colony variant phenotype, as seen in a more chronic-persistent course of disease such as in cystic fibrosis (31). Yet, the establishing of a straightforward, unequivocal strategy to downregulate staphylococcal virulence using a cheap, simple, relatively nontoxic, resorbable compound such as SAL may be seen as major progress in the development of intervening strategies in addition to antimicrobial drugs.

Potential directions of future research

The study by Kupferwasser et al. (27) leaves a number of open questions. Firstly, is there any role of SAL in established endocarditis? As downregulation of attachment factors may be of prime importance to prevent initial steps of pathogenesis, SAL may come too late for a salutary effect in treatment. In fact, the above-mentioned “paradoxic” effect due to hyperexpression of α-hemolysin may be abrogated, resulting in diminished release of platelet microbicidal proteins. Secondly, how do the findings regarding agr suppression relate to the findings of others, that in a serum milieu (32) or in established infection (33), agr expression is already largely diminished, and other regulators such as sae may play a more prominent role in the in vivo infection? Lastly, what is the mechanism of the effect of SAL on S. aureus regulation? SAL is known to exert a plethora of effects on various eukaryotic and prokaryotic cells. More specifically, SAL treatment enhances resistance of S. aureus to fluoroquinolones and fusidic acid. Even more interesting, SAL inhibits biofilm production in Staphylococcus epidermidis (34), apparently because of multiple effects on proteinaceous and nonproteinaceous cell wall and cell surface components (35). Biofilm production in S. aureus (36) and S. epidermidis (37) has been demonstrated to depend on the icaADBC gene cluster that confers production of the polysaccharide intercellular adhesin (PIA, also known as PS/A). Expression of the icaADBC gene cluster is environmentally controlled and, at least in part, regulated by sigB. sigB expression, on the other hand, is controlled by a cascade of sigB activators and inhibitors (38).

The observations by Kupferwasser et al. (27) shed substantially more light onto the patchwork of information concerning the effect of SAL on staphylococci, and they relate it to its potential as a therapeutic compound. Given this exciting new prospect for a widely used and established drug, additional research into the molecular events that result from staphylococcal exposure to SAL is now warranted.

Acknowledgments

The author’s research is supported in part by the Deutsche Forschungsgemeinschaft (DFG Priority Programmes 1047 and 1130) and by a grant from the University of Saarland.

Footnotes

See the related article beginning on page 222.

Conflict of interest: The author has declared that no conflict of interest exists.

Nonstandard abbreviations used: clumping factor A (ClfA); acetylsalicylic acid (ASA); salicylic acid (SAL).

References

  1. Ogston, A. Micrococcus poisoning. J. Anat. 1882. 17:24-58.
  2. Cabell, CH, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch. Intern. Med. 2002. 162:90-94.
    View this article via: PubMed CrossRef
  3. Bayer, A.S., and Scheld, W.M. 2000. Endocarditis and intravascular infections. In Principles and practice of infectious diseases. G.L. Mandell, J.E. Bennett, and R. Dolin, editors. Churchill Livingstone. Philadelphia, Pennsylvania, USA. 857–902.
  4. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections: Los Angeles County, California, 2002–2003 MMWR Morb. Mortal. Wkly. Rep. 2003. 52:88.
  5. Daum, RS, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J. Infect. Dis. 2002. 186:1344-1347.
    View this article via: PubMed CrossRef
  6. Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002 [erratum 2002, 51:931] MMWR Morb. Mortal. Wkly. Rep. 2002. 51:902.
    View this article via: PubMed
  7. Lowy, FD. Medical progress: Staphylococcus aureus infections. N. Engl. J. Med. 1998. 339:520-532.
    View this article via: PubMed CrossRef
  8. Foster, TJ, Höök, M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998. 6:484-488.
    View this article via: PubMed CrossRef
  9. Palma, M, Haggar, A, Flock, JI. Adherence of Staphylococcus aureus is enhanced by an endogenous secreted protein with broad binding activity. J. Bacteriol. 1999. 181:2840-2845.
    View this article via: PubMed
  10. Hussain, M, et al. Identification and characterization of a novel 38.5-kilodalton secretory protein of Staphylococcus aureus with extended-spectrum binding activitiy for extracellular matrix and plasma. J. Bacteriol. 2001. 183:6778-6786.
    View this article via: PubMed CrossRef
  11. Sinha, B, et al. Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells. Infect. Immun. 2000. 68:6871-6878.
    View this article via: PubMed CrossRef
  12. Que, YA, et al. Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. Infect. Immun. 2001. 69:6296-6302.
    View this article via: PubMed CrossRef
  13. Cheung, AL, Nast, CC, Bayer, AS. Selective activation of sar promoters with the use of green fluorescent protein transcriptional fusions as the detection system in the rabbit endocarditis model. Infect. Immun. 1998. 66:5988-5993.
    View this article via: PubMed
  14. Xiong, Y-Q, et al. Activation and transcriptional interaction between agr RNAII and RNAIII in Staphylococcus aureus in vitro and in an experimental endocarditis model. J. Infect. Dis. 2002. 186:668-677.
    View this article via: PubMed CrossRef
  15. Durack, DT. Experimental bacterial endocarditis. IV. Structure and function of the very early lesions. Br. J. Exp. Pathol. 1975. 115:81-80.
  16. Clawson, CC, White, JG, Herzberg, MC. Platelet interaction with bacteria. VI. Contrasting the role of fibrinogen and fibronectin. Am. J. Hematol. 1980. 9:43-53.
    View this article via: PubMed CrossRef
  17. Herrmann, M, Lai, QJ, Albrecht, RM, Mosher, DF, Proctor, RA. Adhesion of Staphylococcus aureus to surface-bound platelets: role of fibrinogen/fibrin and platelet integrins. J. Infect. Dis. 1993. 167:312-322.
    View this article via: PubMed
  18. Siboo, IR, Cheung, AL, Bayer, AS, Sullam, PM. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect. Immun. 2001. 69:3120-3127.
    View this article via: PubMed CrossRef
  19. Sullam, PM, Bayer, AS, Foss, WM, Cheung, AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect. Immun. 1996. 64:4915-4921.
    View this article via: PubMed
  20. Heilmann, C, Herrmann, M, Kehrel, BE, Peters, G. Platelet-binding domains in 2 fibrinogen-binding proteins of Staphylococcus aureus identified by phage display. J. Infect. Dis. 2002. 186:32-39.
    View this article via: PubMed CrossRef
  21. Yeaman, MR. The role of platelets in antimicrobial host defense. Clin. Infect. Dis. 1997. 25:951-968.
    View this article via: PubMed CrossRef
  22. Bayer, AS, et al. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect. Immun. 1997. 65:4652-4660.
    View this article via: PubMed
  23. Nicolau, DP, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect. Immun. 1993. 61:1593-1595.
    View this article via: PubMed
  24. Taha, TH, Durrant, SS, Mazeika, PK, Nihoyannopoulos, P, Oakley, CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J. Intern. Med. 1992. 231:543-546.
    View this article via: PubMed
  25. Nicolau, DP, Tessier, PR, Nightingale, CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int. J. Antimicrob. Agents. 1999. 11:159-161.
    View this article via: PubMed CrossRef
  26. Kupferwasser, LI, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation. 1999. 99:2791-2797.
    View this article via: PubMed
  27. Kupferwasser, LI, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J. Clin. Invest. 2003. 112:222-233. doi:10.1172/JCI200316876.
    View this article via: JCI.org PubMed
  28. Cheung, AL, et al. Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis. J. Clin. Invest. 1994. 94:1815-1822.
    View this article via: JCI.org PubMed CrossRef
  29. Novick, RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 2003. 48:1429-1449.
    View this article via: PubMed CrossRef
  30. Proctor, RA, et al. Two diarylurea electron transport inhibitors reduce Staphylococcus aureus hemolytic activity and protect cultured endothelial cells from lysis. Antimicrob. Agents Chemother. 2002. 46:2333-2336.
    View this article via: PubMed CrossRef
  31. Kahl, B, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 1998. 177:1023-1029.
    View this article via: PubMed
  32. Yarwood, JM, McCormick, JK, Paustian, ML, Kapur, V, Schlievert, PM. Repression of the Staphylococcus aureus accessory gene regulator in serum and in vivo. J. Bacteriol. 2002. 184:1095-1101.
    View this article via: PubMed CrossRef
  33. Wolz, C, Goerke, C, Landmann, R, Zimmerli, W, Fluckiger, U. Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect. Immun.> 2002. 70>:2758-2762.
    View this article via: PubMed
  34. Teichberg, S, Farber, BF, Wolff, AG, Roberts, B. Salicylic acid decreases extracellular biofilm production by Staphylococcus epidermidis: electron microscopic analysis. J. Infect. Dis. 1993. 167:1501-1503.
    View this article via: PubMed
  35. Muller, E, Al Attar, J, Wolff, AG, Farber, BF. Mechanism of salicylate-mediated inhibition of biofilm in Staphylococcus epidermidis. J. Infect. Dis. 1998. 177:501-503.
    View this article via: PubMed
  36. McKenney, D, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science. 1999. 284:1523-1527.
    View this article via: PubMed CrossRef
  37. Heilmann, C, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol. Microbiol. 1996. 20:1083-1091.
    View this article via: PubMed CrossRef
  38. Kullik, I, Giachino, P. The alternative sigma factor ςB in Staphylococcus aureus: regulation of the sigB operon in response to growth phase and heat shock. Arch. Microbiol. 1997. 167:151-159.
    View this article via: PubMed CrossRef
  39. Chavakis, T, et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med. 2002. 8:687-693.
    View this article via: PubMed CrossRef
  40. Lee, LY, et al. The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell–mediated responses. J. Clin. Invest. 2002. 110:1461-1471. doi:10.1172/JCI200216318.
    View this article via: JCI.org PubMed

This article Copyright © 2003, The American Society for Clinical Investigation.